AML | Bladder | CML | Colorectal | Endometrial | Glioma | NSCL | Pancreatic | Renal | SCL | Thyroid | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
5 years Survival [%] | 23.6 | 78.1 | 55.2 | 63.6 | 68.6 | 33.4 | 18 | 5.5 | 69.5 | 6.2 | 97.2 | |
Nominal Betti | 107 | 20 | 114 | 51 | 45 | 128 | 50 | 38 | 51 | 149 | 24 | |
Best Betti [single node elimination] | 95 | 15 | 101 | 41 | 35 | 109 | 37 | 29 | 34 | 131 | 17 | |
Best Betti [double node elimination] | 83 | 11 | 88 | 31 | 26 | 90 | 29 | 21 | 26 | 113 | 10 | |
Paired node elimination | HRAS – MAPK3 | ITGA2 – ITGA3 | ||||||||||
ARAF – MAPK3 | ITGA2 – ITGA6 | |||||||||||
RAF1 – MAPK3 | ITGA3 – ITGA6 | |||||||||||
HRAS – FLT3 | NRAS – MAPK3 | ITGA2 – ITGA2B | ||||||||||
HRAS – NRAS | HRAS – MAPK1 | AKT1 – AKT2 | AKT1 – AKT2 | NRAS – HRAS | ITGA3 – ITGA2B | HRAS – NRAS | ||||||
FLT3 – NRAS | ARAK – MAPK1 | AKT1 – AKT3 | AKT1 – AKT3 | ILK – PDPK1 | NRAS – KRAS | EGFR – KRAS | NFKB1 – KRAS | HIF1A – GAB1 | ITGA6 – ITGA2B | HRAS – KRAS | ||
HRAS – KRAS | RAF1 – MAPK1 | AKT2 – AKT3 | AKT2 – AKT3 | HRAS – KRAS | ERBB2 – KRAS | RELA – KRAS | GAB1 – EPAS1 | ITGA2 – ITGB1 | NRAS – KRAS | |||
FLT3 – KRAS | NRAS – MAPK1 | ITGA3 – ITGB1 | ||||||||||
NRAS – KRAS | MAPK3 – KRAS | ITGA6 – ITGB1 | ||||||||||
MAPK1 – KRAS | ITGA2B – ITGB1 | |||||||||||
MAPK3 – BRAF | ITGA2 – ITGAV | |||||||||||
MAPK1 - BRAF | ITGA3 - ITGAV |